secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0000950170-24-046197
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics licenses full data and IP for LX2006 FA cardiomyopathy gene therapy from Cornell
--------------------------------------------------------------------------------

- Upfront fees total $600,000; potential regulatory milestones up to $2.1M and commercial milestones up to $100M.
- Exclusive license to patent rights and non-exclusive know-how for AAVrh.10hFXN (LX2006), including right to reference IND.
- 11 participants dosed across two trials (Lexeo's SUNRISE-FA and Weill Cornell Phase 1A); no treatment-related SAEs reported.
- Interim clinical data readout expected mid-2024, combining data from both studies with up to 18-month follow-up.
- LX2006 has FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations for FA cardiomyopathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/0000950170-24-046197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/lxeo-20240422.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-046197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer